Award
Award #75N98026D00082
Long-Term Progenics Contract for NeuroSeq Amyloid Radiotracer in Aging Study
Buyer
National Institutes of Health
Award Amount
$1,211,250.00
Ceiling
$1,211,250.00
Awarded
September 22, 2026
Period of Performance
Sep 22, 2026 – Sep 21, 2031
Identifier
75N98026D00082
NAICS
325412
This award is a multi-year indefinite delivery vehicle (IDV) contract awarded to Progenics Pharmaceuticals Inc, a specialized pharmaceutical and biomedical company. The contract focuses on procuring the NeuroSeq Amyloid Radiotracer, a critical product used in the Baltimore Longitudinal Study of Aging (BLSA) to advance research on neurodegenerative diseases related to amyloid accumulation. This contract is significant for supporting vital aging and neurological research by ensuring a steady supply of this specialized radiotracer over the duration of the study. The scope involves the consistent delivery of this product throughout the performance period, reinforcing a long-term commitment to critical scientific investigations. Awarded through a non-competitive process under an IDV mechanism, this contract spans approximately five years, highlighting its importance in sustaining ongoing research efforts in the public health sector.
Description
NEURASEQ AMYLOID RADIOTRACER ACQUISITION FOR THE BALTIMORE LONGITUDINAL STUDY OF AGING (BLSA)